This is a 45-minute MOC Section 3 accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation and chronic nature of GPP, including its lifelong physical, emotional, and psychosocial impacts. The role of the interleukin-36 (IL-36) receptor pathway in disease pathogenesis, and strategies for managing and preventing GPP flares will also be explored. Particular emphasis will be placed on spesolimab, a recently Health Canada-approved, first-in-class IL-36 receptor antagonist designed specifically for GPP treatment.
This program has received financial support from Boehringer Ingelheim in the form of an unrestricted educational grant.